Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $5.76M by Medicaid between Jan 2018 and Dec 2024, across 111 billing codes. Its largest line is 99284, emergency room visit (serious) — 26% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
REDWOOD CITY, CA 94063
REDWOOD CITY, CA 94063
33aNPI1386714814assigned 11/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.76M
24GClaims233,653
24DCodes billed111
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#215 of 410
Median peer was paid$6.90M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,558 | $211K | |
| 2019 | 23,958 | $276K | |
| 2020 | 18,305 | $289K | |
| 2021 | 27,394 | $329K | |
| 2022 | 38,590 | $431K | |
| 2023 | 52,845 | $515K | |
| 2024incomplete | 59,003 | $3.71M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 5,400 | 5,017 | $1.52M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 4,217 | 4,053 | $733K |
| 0450 | Emergency room services | 10% | 13,411 | 11,520 | $576K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.3% | 936 | 883 | $537K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.7% | 4,373 | 4,123 | $387K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.1% | 2,117 | 2,077 | $352K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 2,339 | 2,238 | $219K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.6% | 2,451 | 2,378 | $147K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 4,158 | 3,929 | $109K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 5,885 | 5,378 | $80K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 3,373 | 3,106 | $78K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 1,961 | 1,897 | $73K |
99 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 12,753 | $59K |
| 80051 | <1% | 9,501 | $49K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,456 | $38K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,104 | $35K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 244 | $34K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,482 | $34K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 839 | $31K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,604 | $29K |
| 82565 | <1% | 10,216 | $29K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 273 | $25K |
| 84520 | <1% | 9,487 | $25K | |
| G0378 | Hospital observation service, per hour | <1% | 168 | $25K |
| 82947 | <1% | 9,569 | $24K | |
| 83690 | <1% | 5,242 | $23K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,546 | $22K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,165 | $22K |
| 84460 | <1% | 6,047 | $19K | |
| 84075 | <1% | 5,416 | $19K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 402 | $19K |
| 82247 | <1% | 5,948 | $19K | |
| 84450 | <1% | 5,877 | $19K | |
| 84484 | <1% | 2,991 | $18K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,356 | $17K |
| 83880 | <1% | 1,284 | $15K | |
| J3490 | Unclassified drugs | <1% | 1,009 | $15K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 291 | $15K |
| 84703 | <1% | 2,666 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,991 | $11K |
| 81001 | <1% | 7,523 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,036 | $11K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 716 | $11K |
| 87040 | <1% | 1,029 | $11K | |
| 87631 | <1% | 335 | $10K | |
| 99070 | <1% | 4,405 | $10K | |
| 83605 | <1% | 1,299 | $9K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 553 | $9K |
| 86900 | <1% | 259 | $9K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,827 | $9K |
| 83735 | <1% | 2,260 | $8K | |
| 82077 | <1% | 964 | $8K | |
| 73630 | <1% | 188 | $7K | |
| 84702 | <1% | 1,194 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,037 | $7K |
| 85610 | <1% | 2,320 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 663 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,350 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,142 | $5K |
| 73610 | <1% | 92 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $5K |
| 0270 | <1% | 843 | $4K | |
| 81003 | <1% | 3,466 | $4K | |
| 84100 | <1% | 1,652 | $4K | |
| 80306 | <1% | 454 | $4K | |
| 73560 | <1% | 95 | $4K | |
| 85379 | <1% | 741 | $4K | |
| 73030 | <1% | 55 | $3K | |
| 0637 | <1% | 14,227 | $3K | |
| 87088 | <1% | 1,237 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 125 | $3K |
| 86901 | <1% | 259 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 125 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 681 | $2K |
| 71250 | <1% | 13 | $2K | |
| 82962 | <1% | 926 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 171 | $2K |
| 85652 | <1% | 1,850 | $2K | |
| 93976 | <1% | 29 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 455 | $1K |
| 73130 | <1% | 27 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 28 | $1K |
| 86850 | <1% | 117 | $1K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 13 | $1K |
| 93971 | <1% | 12 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $769.40 |
| 96376 | <1% | 175 | $722.97 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 186 | $683.92 |
| 0250 | <1% | 1,599 | $642.06 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 364 | $606.65 |
| 70486 | <1% | 12 | $598.14 | |
| 0710 | <1% | 362 | $568.33 | |
| 85730 | <1% | 144 | $515.74 | |
| 86140 | <1% | 101 | $461.02 | |
| 85378 | <1% | 103 | $444.82 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 213 | $369.01 |
| 80179 | <1% | 25 | $253.47 | |
| 82248 | <1% | 87 | $243.77 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 90 | $194.08 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 131 | $175.02 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 22 | $152.69 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 45 | $106.18 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 137 | $78.90 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 13 | $77.46 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 66 | $66.12 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12 | $51.82 |
| 85027 | <1% | 28 | $47.40 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 14 | $35.68 |
| 84132 | <1% | 27 | $21.11 | |
| 0258 | <1% | 93 | $8.78 | |
| 0370 | 0% | 237 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOYD, CHRIS (INTERIM SVP/AREA MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Northern Virginia Checker Cab LLC | Manassas, VA | $1.78M |
| Alexxandria Yellow Cab INC | Alexandria, VA | $512K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.